AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
304.16B
Market cap304.16B
Price-Earnings ratio
29.39
Price-Earnings ratio29.39
Dividend yield
1.62%
Dividend yield1.62%
Average volume
1.80M
Average volume1.80M
High today
$196.90
High today$196.90
Low today
$194.31
Low today$194.31
Open price
$194.88
Open price$194.88
Volume
1.17M
Volume1.17M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

With a market cap of 304.16B, AstraZeneca(AZN) trades at $195.94. The stock has a price-to-earnings ratio of 29.39 and currently yields dividends of 1.6%.

On 2026-03-31, AstraZeneca(AZN) stock moved within a range of $194.31 to $196.90. With shares now at $195.94, the stock is trading +0.8% above its intraday low and -0.5% below the session's peak.

Trading volume for AstraZeneca(AZN) stock has reached 1.17M, versus its average volume of 1.8M.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

AZN News

The Wall Street Journal 3h
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

Regional expansion was probably the biggest driver of growth for the treatment, Chief executive of AstraZeneca’s rare-disease unit Alexion, Marc Dunoyer said. C...

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
TipRanks 4h
AstraZeneca announces results of 3 trials of efzimfotase alfa

AstraZeneca (AZN) announced the efzimfotase alfa Phase III clinical programme, designed to study a broad hypophosphatasia, HPP, patient population, demonstrated...

TipRanks 9h
AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

24/7 Wall St. 1d
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings By Joel South Published Mar 30, 9:58AM EDT Quick Read AstraZeneca (AZN) reported FY2025 revenu...

Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings
TipRanks 2d
Jacobio Secures US$100 Million Upfront From AstraZeneca for Pan-KRAS Cancer Drug

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 4d
AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

AstraZeneca reported that its antibody drug tozorakimab succeeded in two Phase 3 trials in chronic obstructive pulmonary disease (COPD), targeting a broad COPD...

AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story
TipRanks 4d
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) is running a new early-stage cancer trial called “A Modular Ope...

The Wall Street Journal 4d
AstraZeneca Shares Surge on COPD Trial Success

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms...

AstraZeneca Shares Surge on COPD Trial Success
Nasdaq 4d
AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study

(RTTNews) - Shares of AstraZeneca PLC (AZN) are gaining about 4 percent on Friday morning trading after the company announced positive high-level results from t...

AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study
Benzinga 4d
AstraZeneca Strengthens Position In COPD Race With Successful Trials

Positive COPD Data Tozorakimab is a monoclonal antibody targeting interleukin-33 (IL-33), which inhibits the signalling of the reduced and oxidised forms of IL...

AstraZeneca Strengthens Position In COPD Race With Successful Trials

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.